Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | POLRMT | O00411 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6141746 | 0.84 | POLG (0.51) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL17215886 | 0.84 | POLG (0.51) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL25396644 | 0.84 | POLG (0.51) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL585724 | 0.84 | POLG (0.51) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL18797120 | 0.83 | P2RY6 (0.55) | P2RY2P2RY6P2RY4 | |
| SCHEMBL6038233 | 0.83 | POLG (0.50) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL22577336 | 0.82 | PDE3A (0.42) | POLB | |
| SCHEMBL597307 | 0.81 | POLG (0.49) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL10900419 | 0.81 | POLG (0.49) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL27451032 | 0.81 | POLG (0.49) | POLGP2RY2P2RY6P2RY4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622661-A1 | CODON-OPTIMIZED OLIGONUCLEOTIDE FOR INDUCTION OF ELASTIN DE-NOVO SYNTHESIS IN MAMMALS | Eberhard Karls Universität Tübingen, Medizinische Fakultät (DE) | 2025-10-01 | — | — | EP | disclosed |
| CN-120202025-A | Compositions for enhancing nucleic acid delivery | 深圳鸿生生物科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-112638362-B | Dry powder formulations of messenger RNA | 川斯勒佰尔公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119451988-B | Anti-B7-H3 antibodies and uses thereof | 乐普创一生物科技（上海）有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-119930823-A | Anti-CCR 8 antibodies and uses thereof | 乐普创一生物科技（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119735678-A | Tumor antigen dependent CD40 agonist single domain antibodies | 乐普创一生物科技（上海）有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119662655-A | Application of RNA molecule and composition thereof in tumor immunotherapy | 武汉厚先生物医药有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119462954-A | 5T4/CD40 bispecific antibodies | 乐普创一生物科技（上海）有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119451988-A | Anti-B7-H3 antibodies and uses thereof | 乐普创一生物科技（上海）有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119110732-A | Gene editing for improving joint function | 奥泽生物疗法公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-116059170-A | Stereochemically enriched compositions for delivery of nucleic acids | 川斯勒佰尔公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916158-A | Lipid nanoparticle formulations for mRNA delivery | 翻译生物公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115515559-A | Rectal delivery of messenger RNA | 翻译生物公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-115461042-A | Improved method for preparing MRNA-loaded lipid nanoparticles | 翻译生物公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-115443338-A | Methods and compositions for messenger RNA purification | 翻译生物公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-115427021-A | Improved method for preparing MRNA-loaded lipid nanoparticles | 翻译生物公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-106795142-B | Stereochemically enriched compositions for delivery of nucleic acids | 川斯勒佰尔公司 | 2022-11-04 | — | — | CN | disclosed |
| US-11479768-B2 | ATP-binding cassette family coding polyribonucleotides and formulations thereof | ETHRIS GMBH (DE) | 2022-10-25 | — | — | US | disclosed |
| CN-115244061-A | Reagents and their use for modular enantioselective synthesis of C-P bonds | 百时美施贵宝公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-109072223-B | Multimeric coding nucleic acids and uses thereof | 川斯勒佰尔公司 | 2022-10-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479768-B2 | ATP-binding cassette family coding polyribonucleotides and formulations thereof | ABCD3, ABCC3, ABCF1 | POLG 319/4885P2RY2 1514/4885P2RY6 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.